分类
外汇交易技巧和技巧

如何设置社交交易 Expert Option

如何设置社交交易 Expert Option

About Stat-Ease

Contact

Phone: 612.378.如何设置社交交易 Expert Option 9449

Newsletter

Sign up for our bi-monthly newsletter with frequently asked questions about 如何设置社交交易 Expert Option design of experiments.

© Stat-Ease, Inc. 2022. Design-Expert® Software is a 如何设置社交交易 Expert Option registered trademark of Stat-Ease, Inc.
Privacy Policy. Terms of Service.

如何设置社交交易 如何设置社交交易 Expert Option Expert Option

CCO Register Now Banner
  • Cardiology
  • Endocrinology
  • HIV
  • Immunology
  • InfectiousDisease
  • Neurology-Psychiatry
  • Oncology

Personalize your Recommended Content Settings Immediate answers to patient care questions

Addition of information from the National Comprehensive Cancer Network’s guideline on Cancer in People With HIV

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and 如何设置社交交易 Expert Option Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis

Introduction: Ulcerative colitis (UC) is a chronic inflammatory condition of the gastrointestinal tract involving a dysregulated immune response. Sphingosine-1-phosphate (S1P) is involved in immune cell regulation. S1P-receptor 如何设置社交交易 Expert Option modulators, such as ozanimod, inhibit lymphocyte migration and have therapeutic potential in UC.

Areas covered: Ozanimod is the first S1P-receptor modulator approved for the treatment of UC. It acts as a functional antagonist, causing internalization of S1P receptors on T-cells. Lymphocyte egress from lymph nodes is inhibited, and migration to sites of active inflammation is curtailed. There are several S1P-receptor subtypes, present in various organs, which inform understanding of ozanimod's side-effect profile including bradycardia and macular edema. In this review, the authors discuss the mechanism of action, pharmacokinetics, clinical efficacy, and safety profile of ozanimod in the treatment of patients with moderate-to-severe UC.

Expert opinion: The S1P-receptor modulator ozanimod is an oral small molecule with a rapid onset of action and a novel therapeutic mechanism in the treatment of UC. It is an effective treatment both in bio-naïve and bio-exposed patients. Although the safety profile of ozanimod looks favorable, more long-term data are needed. Further studies are required to compare ozanimod to currently available therapies to best define its positioning in UC treatment algorithms.

Keywords: Inflammatory bowel disease; ozanimod; small molecules; sphingosine-1-phosphate receptor modulators; ulcerative colitis.

Similar articles

Choi D, Stewart AP, Bhat S. Choi D, et al. Ann Pharmacother. 2022 May;56(5):592-599. doi: 10.1177/10600280211041907. Epub 2021 Aug 22. Ann Pharmacother. 2022. PMID: 34423657 Review.

Aoun R, Hanauer S. Aoun R, et al. Expert Rev Gastroenterol Hepatol. 2022 May;16(5):411-423. doi: 10.1080/17474124.2022.2065258. Expert Rev Gastroenterol Hepatol. 2022. PMID: 35400292 Review.

Antonelli EK, Del Sordo R, Morelli O, Villanacci V, Bassotti G. Antonelli EK, et al. Drugs 如何设置社交交易 Expert Option Today (Barc). 2022 Jul;58(7):351-367. doi: 10.1358/dot.2022.58.7.3408818. Drugs Today (Barc). 2022. PMID: 35851870 Review.

Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, Danese S. Argollo M, et al. Expert Opin Biol Ther. 2020 Apr;20(4):413-420. doi: 10.1080/14712598.2020.1732919. Epub 2020 Feb 25. Expert Opin Biol Ther. 2020. PMID: 32093531 Review.

Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, 如何设置社交交易 Expert Option Aranda R, Gujrathi S, Olson A; TOUCHSTONE Study Group. Sandborn WJ, et al. N Engl J Med. 2016 May 5;374(18):1754-62. doi: 10.1056/NEJMoa1513248. N Engl J Med. 2016. PMID: 27144850 Clinical Trial.

Pityriasis versicolor: an update on pharmacological treatment options

Introduction: Pityriasis versicolor (PV) is a superficial fungal infection caused 如何设置社交交易 Expert Option by Malassezia species; a yeast that naturally colonizes on the skins surface. High efficacy rates are generally obtained with both topical and systemic treatments. However, recurrence rates following successful treatment remain high and there are no dosage guidelines available for administration of systemic antifungal agents that carry risks of adverse events.

Areas covered:如何设置社交交易 Expert Option This review focused on providing an overview of existing treatments for PV and an introduction to new treatments. A literature search was conducted using the search strategy, pityriasis versicolor OR tinea versicolor. Over the past decade, few new treatments have been introduced, but the efficacy and the dosing regimens of existing treatments have been systematically reviewed. The results of these reviews are discussed.

Expert opinion: Existing topical and systemic agents are both effective 如何设置社交交易 Expert Option treatments against PV. Previous dosage recommendations for systemic agents have been modified based on recent evidence elucidated in systematic reviews. However, the absence of standardized collection and reporting practices in clinical trials 如何设置社交交易 Expert Option 如何设置社交交易 Expert Option precludes any conclusions to be drawn regarding the efficacy and safety of topical and systemic agents in comparison or in concert with each other.

Keywords: pityriasis versicolor; systemic antifungal; tinea versicolor; topical antifungal; treatment.

Similar articles

Gupta AK, Kogan N, Batra R. Gupta 如何设置社交交易 Expert Option AK, et al. Expert Opin Pharmacother. 2005 Feb;6(2):如何设置社交交易 Expert Option 如何设置社交交易 Expert Option 165-78. doi: 10.1517/14656566.6.2.165. Expert Opin Pharmacother. 2005. PMID: 15757415 Review.

Sharma A, Rabha D, Ahmed G. Sharma A, et al. Indian J Dermatol Venereol Leprol. 2017 Mar-Apr;83(2):如何设置社交交易 Expert Option 249-251. doi: 10.4103/0378-6323.193617. Indian J Dermatol Venereol Leprol. 2017. PMID: 27852993 No abstract available.

Kallini JR, Riaz F, Khachemoune 如何设置社交交易 Expert Option A. Kallini JR, et al. Int J Dermatol. 2014 Feb;53(2):137-41. doi: 10.1111/ijd.12345. Epub 2013 Dec 10. Int J Dermatol. 2014. PMID: 24320140 Review.

Gupta AK, Bluhm R, Summerbell R. Gupta AK, et al. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33. doi: 10.1046/j.1468-3083.2002.00378.如何设置社交交易 Expert Option x. J Eur Acad Dermatol Venereol. 2002. PMID: 11952286 Review.

Cantrell WC, Elewksi BE. Cantrell WC, et al. J Drugs Dermatol. 2014 Jul;13(7):855-9. J Drugs Dermatol. 2014. PMID: 25007370 Clinical Trial.

Cited by

Hobi S, Cafarchia C, Romano V, Barrs VR. Hobi 如何设置社交交易 Expert Option S, et al. J Fungi (Basel). 2022 Jul 4;8(7):708. doi: 10.3390/jof8070708. J Fungi (Basel). 2022. PMID: 35887463 Free PMC article. Review.

Georgescu SR, Mitran CI, Mitran MI, Matei C, Popa GL, Erel O, Tampa M. Georgescu SR, et al. J Clin Med. 2022 Mar 9;11(6):1507. doi: 10.3390/jcm11061507. J Clin Med. 2022. PMID: 35329832 Free PMC article. Review.